Search

Your search keyword '"Geissler M"' showing total 709 results
Start Over Author "Geissler M"
709 results on '"Geissler M"'

1. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI

Author

Alig, A.H.S., Modest, D.P., Stintzing, S., Heinrich, K., Geissler, M., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Held, S., Moosmann, N., Stahler, A., Tannapfel, A., Giessen-Jung, C., Jung, A., Weiss, L., and Heinemann, V.

Published
2024
Full Text
View/download PDF

2. Photo-induced pair production and strong field QED on Gemini

Author

Keitel, CH, Di Piazza, A, Paulus, GG, Stoehlker, T, Clark, EL, Mangles, S, Najmudin, Z, Krushelnick, K, Schreiber, J, Borghesi, M, Dromey, B, Geissler, M, Riley, D, Sarri, G, and Zepf, M

Subjects
Physics - Plasma Physics, High Energy Physics - Experiment, High Energy Physics - Phenomenology
Abstract

The extreme intensities obtainable with lasers such as Gemini allow non-linear QED phenomena to be investigated according to our calculations. Electron-positron pair production from a pure vacuum target, which has yet to be observed experimentally, is possibly the most iconic process. Beyond pair-production our campaign will allow the experimental investigation of currently unexplored extreme radiation regimes, like the quantum radiation dominated regime (where quantum and self-field effects become important) and non-linear Compton scattering. This is the first experiment in a multi-part campaign proposed by a major international collaboration to investigate non-linear QED. This proposal is for the first experiment in a series of 3 to achieve our most high-profile experimental goal of pair production in vacuum, but each experiment is designed to have its own tangible high-profile outcome.

Published
2021

4. Between Vision and Reality: Results From A Pan-European Survey on Endoscopic Retrograde Cholangiopancreatography Training Conditions

Author

Hamesch, K., additional, Cahyadi, O., additional, Dimitriadis, S., additional, Hollenbach, M., additional, Dugic, A., additional, Elshaarawy, O., additional, Heinrich, H., additional, Mandorfer, M., additional, Geissler, M. E., additional, Wauters, L., additional, Moris, M., additional, Pellino, G., additional, Acedo, P., additional, Ayari, M., additional, Hadi, A., additional, Sidiropoulos, O., additional, Kunovsky, L., additional, Sousa, P., additional, Dauvarte, H., additional, Král, J., additional, Levink, I., additional, Schlosser, S., additional, and Staudacher, J., additional

Published
2024
Full Text
View/download PDF

5. Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)

Author

Kurreck, A., Geissler, M., Martens, U. M., Riera-Knorrenschild, J., Greeve, J., Florschütz, A., Wessendorf, S., Ettrich, T., Kanzler, S., Nörenberg, D., Seidensticker, M., Held, S., Buechner-Steudel, P., Atzpodien, J., Heinemann, V., Stintzing, S., Seufferlein, T., Tannapfel, A., Reinacher-Schick, A. C., and Modest, D. P.

Published
2020
Full Text
View/download PDF

6. Ion acceleration in multispecies targets driven by intense laser radiation pressure

Author

Kar, S., Kakolee, K. F., Qiao, B., Macchi, A., Cerchez, M., Doria, D., Geissler, M., McKenna, P., Neely, D., Osterholz, J., Prasad, R., Quinn, K., Ramakrisna, B., Sarri, G., Willi, O., Yuan, X. Y., Zepf, M., and Borghesi, M.

Subjects
Physics - Plasma Physics
Abstract

The acceleration of ions from ultra-thin foils has been investigated using 250 TW, sub-ps laser pulses, focused on target at intensities up to $3\times10^{20} \Wcm2$. The ion spectra show the appearance of narrow band features for proton and Carbon peaked at higher energy (in the 5-10 MeV/nucleon range) and with significantly higher flux than previously reported. The spectral features, and their scaling with laser and target parameters, provide evidence of a multispecies scenario of Radiation Pressure Acceleration in the Light Sail mode, as confirmed by analytical estimates and 2D Particle In Cell simulations. The scaling indicates that monoenergetic peaks with more than 100 MeV/nucleon energies are obtainable with moderate improvements of the target and laser characteristics, which are within reach of ongoing technical developments.

Published
2012
Full Text
View/download PDF

7. Dominance of Radiation Pressure in Ion Acceleration with Linearly Polarized Pulses at Intensities of $10^{21}\textrm{W}\textrm{cm}^{-2}$

Author

Qiao, B., Kar, S., Geissler, M., Gibbon, P., Zepf, M., and Borghesi, M.

Subjects
Physics - Plasma Physics, Physics - Accelerator Physics
Abstract

A novel regime is proposed where, employing linearly polarized laser pulses at intensities $10^{21}\textrm{Wcm}^{-2}$ as two order of magnitude lower than earlier predicted [T. Esirkepov et al., Phys. Rev. Lett. 92, 175003 (2004)], ions are dominantly accelerated from ultrathin foils by the radiation pressure, and have monoenergetic spectra. In the regime, ions accelerated from the hole-boring process quickly catch up with the ions accelerated by target normal sheath acceleration (TNSA), and they then join in a single bunch, undergoing a hybrid Light-Sail/TNSA acceleration. Under an appropriate coupling condition between foil thickness, laser intensity and pulse duration, laser radiation pressure can be dominant in this hybrid acceleration. Two-dimensional PIC simulations show that $1.26\textrm{GeV}$ quasimonoenergetic $\textrm{C}^{6+}$ beams are obtained by linearly polarized laser pulses at intensities of $10^{21}\textrm{Wcm}^{-2}$., Comment: 6 pages, 4 figures

Published
2012
Full Text
View/download PDF

8. Design considerations for table-top, laser-based VUV and X-ray free electron lasers

Author

Grüner, F., Becker, S., Schramm, U., Eichner, T., Fuchs, M., Weingartner, R., Habs, D., Meyer-ter-Vehn, J., Geissler, M., Ferrario, M., Serafini, L., van der Geer, B., Backe, H., Lauth, W., and Reiche, S.

Subjects
Physics - Accelerator Physics
Abstract

A recent breakthrough in laser-plasma accelerators, based upon ultrashort high-intensity lasers, demonstrated the generation of quasi-monoenergetic GeV-electrons. With future Petawatt lasers ultra-high beam currents of ~100 kA in ~10 fs can be expected, allowing for drastic reduction in the undulator length of free-electron-lasers (FELs). We present a discussion of the key aspects of a table-top FEL design, including energy loss and chirps induced by space-charge and wakefields. These effects become important for an optimized table-top FEL operation. A first proof-of-principle VUV case is considered as well as a table-top X-ray-FEL which may open a brilliant light source also for new ways in clinical diagnostics., Comment: 6 pages, 4 figures; accepted for publication in Appl. Phys. B

Published
2006
Full Text
View/download PDF

9. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)da randomized phase II trial of the AIO pancreatic cancer group

Author

Seufferlein, T., Uhl, W., Kornmann, M., Alguel, H., Friess, H., Koenig, A., Ghadimi, M., Gallmeier, E., Bartsch, D. K., Lutz, M. P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C. C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., Waldschmidt, D., Bruns, C., Wittel, U., Fichtner-Feigl, S., Daum, S., Hinke, A., Blome, L., Tannapfel, A., Kleger, A., Berger, A. W., Kestler, A. M. R., Schuhbaur, J. S., Perkhofer, L., Tempero, M., Reinacher-Schick, A. C., Ettrich, T. J., Seufferlein, T., Uhl, W., Kornmann, M., Alguel, H., Friess, H., Koenig, A., Ghadimi, M., Gallmeier, E., Bartsch, D. K., Lutz, M. P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C. C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., Waldschmidt, D., Bruns, C., Wittel, U., Fichtner-Feigl, S., Daum, S., Hinke, A., Blome, L., Tannapfel, A., Kleger, A., Berger, A. W., Kestler, A. M. R., Schuhbaur, J. S., Perkhofer, L., Tempero, M., Reinacher-Schick, A. C., and Ettrich, T. J.

Abstract

Background: Data on perioperative chemotherapy in resectable pancreatic ductal adenocarcinoma (rPDAC) are limited. NEONAX examined perioperative or adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in rPDAC (National Comprehensive Cancer Network criteria).Patients and methods: NEONAX is a prospective, randomized phase II trial with two independent experimental arms. One hundred twenty-seven rPDAC patients in 22 German centers were randomized 1 : 1 to perioperative (two preoperative and four post-operative cycles, arm A) or adjuvant (six cycles, arm B) gemcitabine (1000 mg/m2) and nabpaclitaxel (125 mg/m2) on days 1, 8 and 15 of a 28-day cycle.Results: The primary endpoint was disease-free survival (DFS) at 18 months in the modified intention-to-treat (ITT) population [R0/R1-resected patients who started neoadjuvant chemotherapy (CTX) (A) or adjuvant CTX (B)]. The predefined DFS rate of 55% at 18 months was not reached in both arms [A: 33.3% (95% confidence interval [CI] 18.5% to 48.1%), B: 41.4% (95% CI 20.7% to 62.0%)]. Ninety percent of patients in arm A completed neoadjuvant treatment, and 42% of patients in arm B started adjuvant chemotherapy. R0 resection rate was 88% (arm A) and 67% (arm B), respectively. Median overall survival (mOS) (ITT population) as a secondary endpoint was 25.5 months (95% CI 19.7-29.7 months) in arm A and 16.7 months (95% CI 11.6-22.2 months) in the upfront surgery arm. This difference corresponds to a median DFS (mDFS) (ITT) of 11.5 months (95% CI 8.8-14.5 months) in arm A and 5.9 months (95% CI 3.6-11.5 months) in arm B. Treatment was safe and well tolerable in both arms.Conclusions: The primary endpoint, DFS rate of 55% at 18 months (mITT population), was not reached in either arm of the trial and numerically favored the upfront surgery arm B. mOS (ITT population), a secondary endpoint, numerically favored the neoadjuvant arm A [25.5 months (95% CI 19.7-29.7months); arm B 16.7 months (95% CI 11.6-22.2 months)]. There was a d

Published
2023

10. Erlotinib

Author

Steins, M., Thomas, M., Geißler, M., Schlag, Peter M., Series editor, Senn, Hans-Jörg, Series editor, and Martens, Uwe M., editor

Published
2014
Full Text
View/download PDF

11. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group

Author

Seufferlein, T., primary, Uhl, W., additional, Kornmann, M., additional, Algül, H., additional, Friess, H., additional, König, A., additional, Ghadimi, M., additional, Gallmeier, E., additional, Bartsch, D.K., additional, Lutz, M.P., additional, Metzger, R., additional, Wille, K., additional, Gerdes, B., additional, Schimanski, C.C., additional, Graupe, F., additional, Kunzmann, V., additional, Klein, I., additional, Geissler, M., additional, Staib, L., additional, Waldschmidt, D., additional, Bruns, C., additional, Wittel, U., additional, Fichtner-Feigl, S., additional, Daum, S., additional, Hinke, A., additional, Blome, L., additional, Tannapfel, A., additional, Kleger, A., additional, Berger, A.W., additional, Kestler, A.M.R., additional, Schuhbaur, J.S., additional, Perkhofer, L., additional, Tempero, M., additional, Reinacher-Schick, A.C., additional, and Ettrich, T.J., additional

Published
2023
Full Text
View/download PDF

12. Erlotinib

Author

Steins, M., Thomas, M., Geißler, M., and Martens, Uwe M., editor

Published
2010
Full Text
View/download PDF

15. Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”

Author

Novello, S., primary, Torri, V., additional, Grohe, C., additional, Kurz, S., additional, Serke, M., additional, Wehler, T., additional, Meyer, A., additional, Ladage, D., additional, Geissler, M., additional, Colantonio, I., additional, Cauchi, C., additional, Stoelben, E., additional, Ceribelli, A., additional, Kropf-Sanchen, C., additional, Valmadre, G., additional, Borra, G., additional, Schena, M., additional, Morabito, A., additional, Santo, A., additional, Gregorc, V., additional, Chiari, R., additional, Reck, M., additional, Schmid-Bindert, G., additional, Folprecht, G., additional, Griesinger, F., additional, Follador, A., additional, Pedrazzoli, P., additional, Bearz, A., additional, Caffo, O., additional, Dickgreber, N.J., additional, Irtelli, L., additional, Wiest, G., additional, Monica, V., additional, Porcu, L., additional, Manegold, C., additional, and Scagliotti, G.V., additional

Published
2022
Full Text
View/download PDF

19. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer

Author

Novello, S., primary, Torri, V., additional, Grohe, C., additional, Kurz, S., additional, Serke, M., additional, Wehler, T., additional, Meyer, A., additional, Ladage, D., additional, Geissler, M., additional, Colantonio, I., additional, Cauchi, C., additional, Stoelben, E., additional, Ceribelli, A., additional, Kropf-Sanchen, C., additional, Valmadre, G., additional, Borra, G., additional, Schena, M., additional, Morabito, A., additional, Santo, A., additional, Gregorc, V., additional, Chiari, R., additional, Reck, M., additional, Schmid-Bindert, G., additional, Folprecht, G., additional, Griesinger, F., additional, Follador, A., additional, Pedrazzoli, P., additional, Bearz, A., additional, Caffo, O., additional, Dickgreber, N.J., additional, Irtelli, L., additional, Wiest, G., additional, Monica, V., additional, Porcu, L., additional, Manegold, C., additional, and Scagliotti, G.V., additional

Published
2022
Full Text
View/download PDF

23. LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)

Author

Vogel, A., primary, Saborowski, A., additional, Hinrichs, J., additional, Ettrich, T.J., additional, Ehmer, U., additional, Martens, U.M., additional, Mekolli, A., additional, De Toni, E., additional, Berg, T., additional, Geißler, M., additional, Maenz, M., additional, Kirstein, M., additional, and Waldschmidt, D., additional

Published
2021
Full Text
View/download PDF

24. Das Screening auf Mangelernährung ist bei Patienten mit COVID-19 nicht effektiv

Author

Frieling, T, additional, Kösters, K, additional, Schwarzer, S, additional, Kalde, S, additional, Hundorf, C, additional, Krummen, B, additional, Geißler, M, additional, Kuhlbusch-Zicklam, R, additional, Nawrocki, M, additional, Lehmann, M, additional, Streuter, M, additional, Bürger, A, additional, Labuhn, A, additional, Krüger, D, additional, and Schemann, M, additional

Published
2021
Full Text
View/download PDF

26. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

Author

Boeck, S., Hoehler, T., Seipelt, G., Mahlberg, R., Wein, A., Hochhaus, A., Boeck, H.-P., Schmid, B., Kettner, E., Stauch, M., Lordick, F., Ko, Y., Geissler, M., Schoppmeyer, K., Kojouharoff, G., Golf, A., Neugebauer, S., and Heinemann, V.

Published
2008
Full Text
View/download PDF

28. PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

Author

Novello, S., primary, Monica, V., additional, Serke, M., additional, Grohe, C., additional, Meyer, A., additional, Geissler, M., additional, Colantonio, I., additional, Stoelben, E., additional, Cecere, F., additional, Schutte, W., additional, Schumann, C., additional, Valmadre, G., additional, Borra, G., additional, Schena, M., additional, Morabito, A., additional, Santo, A., additional, Chiari, R., additional, Gregorc, V., additional, Reck, M., additional, Manegold, C., additional, Griesinger, F., additional, Follador, A., additional, Ferrari, A., additional, Bearz, A., additional, Caffo, O., additional, Dickgreber, N., additional, Irtelli, L., additional, Wiest, G.h., additional, Sotoparra, H., additional, Spatafora, M., additional, Righi, L., additional, Torri, V., additional, Porcu, L., additional, Arizio, F., additional, and Scagliotti, G., additional

Published
2021
Full Text
View/download PDF

34. Erlotinib

Author

Steins, M., primary, Thomas, M., additional, and Geißler, M., additional

Published
2009
Full Text
View/download PDF

35. A randomized, double-blind, multicenter phase II AIO trial with Gemcitabine plus Sorafenib versus Gemcitabine plus placebo in patients with chemo-naïve advanced or metastatic biliary tract cancer: first safety and efficacy data: V736

Author

Moehler, M., Kanzler, S., Schimanski, C. C., Wörns, M. A., Denzer, U., Kolligs, F., Ebert, M., Distelrath, A., Zeuzem, S., Lammert, F., Geissler, M., Lohse, A., Dollinger, M., Lindig, U., Dürr, M., Lubomierski, N., Kabisch, M., Schadmand-Fischer, S., and Galle, P. R.

Published
2011

37. 1447P S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO

Author

Haag, G.M., primary, Stocker, G., additional, Lorenzen, S., additional, Ettrich, T.J., additional, Longo, F., additional, Kiani, A., additional, Venerito, M., additional, Trojan, J., additional, Mahlberg, R.J.C., additional, Moosmann, N., additional, Chibaudel, B., additional, Kubicka, S., additional, Greil, R., additional, Daum, S., additional, Geissler, M., additional, Mann, J., additional, and Lordick, F., additional

Published
2020
Full Text
View/download PDF

38. 988P Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC

Author

Vogel, A., primary, Müller, D.W., additional, De Toni, E., additional, Siegler, G.M., additional, Siebler, J., additional, Lindig, U., additional, Müller, T., additional, Schultheiss, M., additional, Geißler, M., additional, Krammer-Steiner, B., additional, Reichart, A., additional, Lammert, F., additional, Prause, C., additional, Walker, M., additional, Al-Batran, S-E., additional, and Kosic, N., additional

Published
2020
Full Text
View/download PDF

39. Stellenwert und qualitative Voraussetzungen der Magnetresonanztomographie für die Therapieplanung beim lokal fortgeschrittenen Rektumkarzinom – interdisziplinäre Empfehlungen

Author

Attenberger, U. I., primary, Rödel, C., additional, Ghadimi, M., additional, Piso, P., additional, Arnold, D., additional, Folprecht, G., additional, Geissler, M., additional, Hegewisch-Becker, S., additional, Heinemann, V., additional, Kasper, S., additional, Modest, D., additional, Reinacher-Schick, A., additional, Seufferlein, T., additional, Stein, A., additional, Stintzing, S., additional, and Hofheinz, R., additional

Published
2020
Full Text
View/download PDF

40. P-78 Early tumour shrinkage, depth of response and survival outcomes for RAS wild-type metastatic colorectal cancer patients classified by baseline tumour load: Retrospective pooled analysis of panitumumab PRIME/PEAK studies

Author

Loupakis, F., primary, Peeters, M., additional, Geissler, M., additional, Modest, D., additional, Valladares-Ayerbes, M., additional, Price, T., additional, Burdon, P., additional, Zhang, Y., additional, and Taieb, J., additional

Published
2020
Full Text
View/download PDF

45. Food-induced anaphylaxis and cofactors – data from the anaphylaxis registry

Author

Worm, M., Scherer, K., Köhli-Wiesner, A., Ruëff, F., Mahler, V., Lange, L., Treudler, R., Rietschel, E., Szepfalusi, Z., Lang, R., Rabe, U., Reese, T., Schwerk, N., Beyer, K., Hompes, S., Bircher, A., Przybilla, B., Hawranek, T., Hansen, G., Friedrichs, F., Merk, H., Tenbrock, K., Lehmann, S., Gerstlauer, M., Kleine-Tebbe, J., Niggemann, B., Dickel, H., Bücheler, M., Bieber, T., Hanfland, J., Schmitt-Grohe, S., Vlajnic, D., Heckmann, V., Nemat, K., Schäkel, K., Nordwig, A., Schuster, A., Schweitzer-Krantz, S., Hillen, U., Kopp, M., Szliska, C., Klinge, J., Neustädter, I., Fuchs, T., Bruns, R., Marsch, C., Kreft, B., Coors, E., Rebien, W., Wedi, B., Pföhler, C., Rett, M., Henzgen, M., Vöhringer, P., Fölster-Holst, R., Hunzelmann, N., Siebenhaar, G., Nestoris, S., Schirpke, C., Grabbe, J., Stichtenoth, G., Ring, J., Brockow, K., Brehler, R., Yildiz, I., Volkmuth, S., Geißler, M., Polz, M., Riffelmann, F., Thies, S., Lepp, U., Rebmann, H., Spindler, T., Klimek, L., Pfaar, O., Brosi, W., Aberer, W., Varga, E., Reider, N., Huttegger, I., Kinaciyan, T., Hoffmann-Sommergruber, K., Eng, P., Helbling, A., Eigenmann, P., Guggenheim, R., and Schmid-Grendelmeier, P.

Subjects
medicine.medical_specialty, Pediatrics, Allergy, Food induced anaphylaxis, Physical activity, registry, food allergens, 03 medical and health sciences, 0302 clinical medicine, 030225 pediatrics, Internal medicine, anaphylaxis, cofactors, medicine, Insect venom, Food allergens, General Environmental Science, 2. Zero hunger, business.industry, General Engineering, Allergic asthma, Atopic dermatitis, medicine.disease, 3. Good health, 030228 respiratory system, Concomitant, General Earth and Planetary Sciences, business, Anaphylaxis, Research Article
Abstract

Food allergens are frequent causes of anaphylaxis. In particular in children and adolescents they are the most frequent elicitors of severe allergic reactions, and in adults food allergens rank third behind insect venom and drugs. Since July 2006 severe allergic reactions from Germany, Austria, and Switzerland are collected in the anaphylaxis registry. Currently 78 hospitals and private practises are connected. From July 2006 until February 2009 1,156 severe allergic reactions were registered. Among children and adolescents (n = 187, age range from 3 months to 17 years) food allergens were the most frequent triggers, comprising 58% of cases. In the adult group (n = 968, 18 - 85 years) food allergens were in the third position (16.3%) behind insect venom and drugs. In children legumes (31%) and in particular peanuts were frequently responsible food allergens, followed by tree nuts (25%) with hazelnut being the most frequent elicitor. In adults fruits (13.4%) most often induced severe food-dependent anaphylaxis, but also animal products (12.2%); among these most frequently crustaceans and molluscs. Cofactors were often suspected in food-dependent anaphylaxis, namely in 39% of the adult group and in 14% of the pediatric group. In adults drugs (22%) and physical activity (10%) were reported to be the most frequent cofactors, in children physical activity was suspected in 8.7% and drugs in 2.6%. Concomitant diseases like atopic dermatitis, allergic asthma, or allergic rhinoconjunctivitis were reported in 78% of children and adolescents and in 67% of the adults. In conclusion, food-induced anaphylaxis, its cofactors and concomitant diseases are age-dependent. The data offers to identify risk factors of anaphylaxis.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results